Literature DB >> 21945732

Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.

Lutz Götze1, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher.   

Abstract

BACKGROUND: Increasing numbers of tyrosine kinase inhibitors (TKIs) were studied and approved for therapy of malignancies and other diseases. The aim of this study was to develop and validate a specific, simple and rapid quantification method for various TKIs in human plasma.
METHODS: A simultaneous test for six TKIs (erlotinib, imatinib, lapatinib, nilotinib, sorafenib, sunitinib) was developed using liquid chromatography tandem mass spectrometry in a multiple reaction monitoring mode. After protein precipitation the specimens were applied to the HPLC system and separated using a gradient of acetonitrile containing 1% formic acid with 10 mM ammoniumformiate on an analytic RP-C18 column.
RESULTS: The calibration range was 10-1000 ng/mL for sunitinib and 50-5000 ng/mL for the other TKIs with coefficients of determination ≥0.99 for all analytes. The intra- and inter day coefficients of variation were ≤15% and the chromatographic run time was 12 min. Plasma specimens were stable for measurement for at least 1 week at 4°C. Clinical applications of the assay are exemplarily discussed.
CONCLUSIONS: This novel high-throughput method is suitable for specific simultaneous determination of different TKIs in routine clinical practice.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945732     DOI: 10.1016/j.cca.2011.09.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

1.  Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; James Fisher; William F Elmquist
Journal:  Chromatographia       Date:  2013-12-01       Impact factor: 2.044

2.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

3.  [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].

Authors:  C Keil; L Götze; P Olbert; R Hofmann; W A Nockher; A Hegele
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

4.  Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.

Authors:  Yuki Ushimaru; Tsuyoshi Takahashi; Kiyokazu Nakajima; Ryugo Teranishi; Toshirou Nishida; Seiichi Hirota; Masaaki Motoori; Takeshi Omori; Ryohei Kawabata; Kazuhiro Nishikawa; Takuro Saito; Kotaro Yamashita; Koji Tanaka; Tomoki Makino; Kazuyoshi Yamamoto; Yukinori Kurokawa; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2022-02-12       Impact factor: 3.402

5.  A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.

Authors:  Jianmei Wu; Richard Wiegand; Patricia LoRusso; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-10-16       Impact factor: 3.205

6.  Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.

Authors:  Varun Khurana; Mukul Minocha; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Metabol Drug Interact       Date:  2014

7.  A Validated RP-HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard.

Authors:  K K Kumar; K E V Nagoji; R V Nadh
Journal:  Indian J Pharm Sci       Date:  2012-11       Impact factor: 0.975

8.  Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Authors:  Jiang Wei; Marcus Freytag; Yvonne Schober; Wolfgang A Nockher; Victor F Mautner; Reinhard E Friedrich; Paul W Manley; Lan Kluwe; Andreas Kurtz
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

9.  Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.

Authors:  Satheeshmanikandan R S Thappali; Kanthikiran Varanasi; Sridhar Veeraraghavan; Rambabu Arla; Sandhya Chennupati; Madheswaran Rajamanickam; Swaroop Vakkalanka; Mukkanti Khagga
Journal:  Sci Pharm       Date:  2012-06-18

10.  Development and Validation of a Rapid RP-HPLC-DAD Analysis Method for the Simultaneous Quantitation of Paclitaxel and Lapatinib in a Polymeric Micelle Formulation.

Authors:  Ebrahim Saadat; Fatemeh Ravar; Pouya Dehghankelishadi; Farid A Dorkoosh
Journal:  Sci Pharm       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.